Shanghai Haohai Biological Technology Co., Ltd. provided financial guidance for the six months ended 30 June 2022. The Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 65,000,000 to RMB 78,000,000 during the Reporting Period, representing a decrease of approximately RMB 166,022,800 to RMB 153,022,800, or approximately 71.86% to 66.24%, as compared to that in 2021(corresponding period in 2021: unaudited net profit attributable to shareholders of the Company of RMB 231,022,827.13).
Shanghai Haohai Biological Technology Co., Ltd.
Equities
6826
CNE100001W69
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
41.05 HKD | -0.85% | -4.98% | +1.86% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.86% | 1.84B | |
-7.38% | 181B | |
-0.46% | 108B | |
-6.98% | 66.12B | |
+2.65% | 50.65B | |
+5.27% | 43.11B | |
+6.10% | 40.74B | |
+19.92% | 31.6B | |
+16.46% | 25.56B | |
-7.00% | 24.16B |
- Stock Market
- Equities
- 6826 Stock
- News Shanghai Haohai Biological Technology Co., Ltd.
- Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022